Evom AI raises seed bridge round from Klim Ventures
What's the deal? Evom AIDealroom has a profile for this one. Try Dealroom →, a South Korean medical AI startup focused on early cardiac diagnosis, has raised a seed bridge round from existing investor Klim VenturesDealroom has a profile for this one. Try Dealroom → (끌림벤처스). The amount was not disclosed. The round follows the company's initial seed investment from Klim Ventures in September 2025 and its selection for the Deep Tech TIPS programme.
Alongside the funding, Evom AI notched two regulatory milestones. Its first product, Evom FastEcho — a digital medical device that automatically classifies 42 echocardiogram views and displays 56 structural measurements — received manufacturing approval from South Korea's Ministry of Food and Drug Safety (MFDS) in March. In May, the company passed its first KGMP (Korea Good Manufacturing Practice) audit, securing a certified quality management system.
Why now? The back-to-back regulatory wins gave Klim Ventures confidence to double down less than a year after its initial cheque. "Securing MFDS registration and KGMP certification for a first product in under a year is exceptional execution," said Nam Hong-gyu, chief executive officer of Klim Ventures. The firm said it valued the team's ability to build regulatory and quality foundations from day one, not just technical capability.
Evom AI was founded by medical AI veterans from Lunit and other companies with experience in AI development, clinical research, global regulatory affairs, and commercialisation. It is now building a cardiac AI portfolio spanning both echocardiography (Evom FastEcho) and electrocardiography (Evom ECG).
What could go wrong? The cardiac AI space is competitive, with established players already selling FDA- and CE-cleared products globally. Evom AI's funding remains modest — a seed bridge with an undisclosed amount — which could limit its ability to scale quickly or pursue international regulatory approvals. Translating regulatory clearance into hospital adoption is another hurdle; clinicians often require extensive validation before trusting AI-assisted diagnostics in practice.
The signal: Evom AI's trajectory reflects a broader pattern in Korean healthtech: startups moving fast from research to regulated product, leveraging the country's relatively streamlined digital medical device pathway. Investor appetite for cardiac AI remains strong as cardiovascular disease continues to be the leading cause of death worldwide. The fact that Klim Ventures re-invested so soon signals conviction that teams with deep domain expertise and regulatory know-how can compress timelines that once took years into months — a trend that could reshape how early-stage medtech companies are valued and funded.
Read more: wowtale.net
